Silence Therapeutics (NASDAQ:SLN) Receives Buy Rating from HC Wainwright

Silence Therapeutics (NASDAQ:SLN - Get Free Report)'s stock had its "buy" rating restated by equities researchers at HC Wainwright in a research report issued to clients and investors on Friday,Benzinga reports. They currently have a $75.00 price target on the stock.

Other research analysts have also issued reports about the stock. The Goldman Sachs Group decreased their price objective on shares of Silence Therapeutics from $4.00 to $3.00 and set a "sell" rating for the company in a report on Friday, May 9th. Morgan Stanley decreased their price target on Silence Therapeutics from $45.00 to $25.00 and set an "overweight" rating for the company in a research note on Friday, May 9th. Chardan Capital decreased their price target on Silence Therapeutics from $55.00 to $35.00 and set a "buy" rating for the company in a research note on Friday, May 9th. Finally, BMO Capital Markets lowered their price objective on Silence Therapeutics from $67.00 to $25.00 and set an "outperform" rating for the company in a report on Tuesday, March 4th. One research analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $33.83.

Silence Therapeutics Trading Down 4.7%

SLN stock traded down $0.26 during midday trading on Friday, hitting $5.33. 77,781 shares of the company's stock were exchanged, compared to its average volume of 304,971. The firm has a 50 day moving average price of $4.13 and a 200-day moving average price of $4.94. Silence Therapeutics has a 12-month low of $1.97 and a 12-month high of $22.47. The stock has a market capitalization of $159.53 million, a price-to-earnings ratio of -3.39 and a beta of 1.41.

Silence Therapeutics (NASDAQ:SLN - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.60) earnings per share for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.42). The company had revenue of $0.14 million for the quarter, compared to analyst estimates of $3.58 million. Silence Therapeutics had a negative return on equity of 62.81% and a negative net margin of 342.00%. On average, sell-side analysts forecast that Silence Therapeutics will post -1.77 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of SLN. Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new stake in shares of Silence Therapeutics during the 4th quarter worth approximately $134,000. JPMorgan Chase & Co. acquired a new stake in Silence Therapeutics in the fourth quarter worth $26,000. Trexquant Investment LP bought a new stake in Silence Therapeutics in the fourth quarter valued at $438,000. Barclays PLC lifted its stake in Silence Therapeutics by 83.8% in the fourth quarter. Barclays PLC now owns 6,126 shares of the company's stock valued at $42,000 after buying an additional 2,793 shares during the last quarter. Finally, Walleye Capital LLC acquired a new position in shares of Silence Therapeutics during the fourth quarter valued at $250,000. 98.73% of the stock is currently owned by institutional investors.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.